The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase III, placebo-controlled trial (SUCCEED) evaluating ridaforolimus as maintenance therapy in advanced sarcoma patients following clinical benefit from prior standard cytotoxic chemotherapy: Long-term (≥ 24 months) overall survival results.
Jean-Yves Blay
Honoraria - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Research Funding - GlaxoSmithKline; Novartis; Pfizer; PharmaMar; Roche
Sant P. Chawla
Honoraria - Cytotech; Cytrex; GlaxoSmithKline; Johnson & Johnson; Merck; Sanofi ; SARC; Threshold
Research Funding - Cytotech; Cytrex; GlaxoSmithKline; Johnson & Johnson; Merck; Sanofi ; SARC; Threshold
Other Remuneration - Cytotech; Cytrex; GlaxoSmithKline; Johnson & Johnson; Merck; Sanofi ; SARC; Threshold
Isabelle Ray-Coquard
Honoraria - Amgen; Merck; Novartis; PharmaMar; Roche; Sanofi
Research Funding - Merck; Novartis; Roche
Axel Le Cesne
Honoraria - Novartis; Pfizer; PharmaMar
Arthur P. Staddon
Research Funding - ARIAD
Mohammed M. Milhem
No relevant relationships to disclose
Nicolas Penel
No relevant relationships to disclose
Richard F. Riedel
Consultant or Advisory Role - Merck
Research Funding - ARIAD
Binh Bui Nguyen
Consultant or Advisory Role - GlaxoSmithKline; Novartis; PharmaMar
Lee D. Cranmer
Honoraria - Merck
Research Funding - Merck
Peter Reichardt
Consultant or Advisory Role - MSD
Honoraria - MSD
Emmanuelle Bompas
No relevant relationships to disclose
Thierry Alcindor
Consultant or Advisory Role - Merck; Pfizer; Sanofi
Daniel A. Rushing
No relevant relationships to disclose
Yang Song
Employment or Leadership Position - Merck
Stock Ownership - Merck
Scot Ebbinghaus
Employment or Leadership Position - Merck
Stock Ownership - Merck
Frank G. Haluska
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
Pierre F. Dodion
Employment or Leadership Position - ARIAD
Stock Ownership - ARIAD
George D. Demetri
Consultant or Advisory Role - Amgen; ARIAD; ArQule; Daiichi Sankyo; GlaxoSmithKline; Infinity; Johnson & Johnson; Merck; Novartis; Pfizer; Roche/Genentech; Sanofi ; ZIOPHARM Oncology
Research Funding - ARIAD; Bristol-Myers Squibb; Daiichi Sankyo; GlaxoSmithKline; Infinity; Johnson & Johnson; Novartis; Pfizer; Sanofi
Expert Testimony - ARIAD/Merck (U)